RPRX

Royalty Pharma
D

RPRX

Arincen67/100B

Royalty Pharma executives and insider trading

Pablo Legorreta reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Royalty Pharma's insiders sold 2,038,771 shares for 92.55M USD in 72 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
72
Shares sold
2,038,771
Value sold
92.55M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
0
0
3 months
12.97M USD
0
6 months
34.57M USD
0
1 year
92.55M USD
0
2 years
93.76M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Terrance Coyne Executive Vice President & Chief Financial Officer—910,40138.96M USD—13 Aug 2026—
Christopher Hite Chairman of Partnering & Investments59480,00027.36M USD—22 Sept 2026—
George W. Lloyd EVP, Investments & CLO—348,35713.53M USD—18 Dec 2025—
Marshall Urist Head of Research & Investments50296,96812.54M USD—5 Oct 2026—
Gregory Norden Director—3,045161.39K USD—14 May 2026—

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
5 Oct 2026Marshall UristSale4,12657.10235.59K USD—Form 4
28 Sept 2026Marshall UristSale4,12657.88238.81K USD4,126Form 4
22 Sept 2026Christopher HiteSale96,07358.515.62M USD274,328Form 4
22 Sept 2026Christopher HiteSale3,92758.93231.40K USD270,401Form 4
18 Aug 2026Christopher HiteSale100,00059.976.00M USD370,401Form 4
13 Aug 2026Terrance CoyneSale9,23058.59540.75K USD1,772Form 4
13 Aug 2026Terrance CoyneSale1,77259.14104.80K USD—Form 4
1 Jul 2026Marshall UristSale9,09955.88508.45K USD—Form 4
30 Jun 2026Christopher HiteSale97,44656.505.51M USD461,953Form 4
30 Jun 2026Christopher HiteSale2,55457.10145.84K USD459,399Form 4
30 Jun 2026Christopher HiteSale29,40056.441.66M USD40,600Form 4
30 Jun 2026Christopher HiteSale60057.0934.25K USD40,000Form 4
24 Jun 2026Marshall UristSale9,09855.18502.07K USD9,099Form 4
23 Jun 2026Christopher HiteSale32,40854.111.75M USD676,991Form 4
23 Jun 2026Christopher HiteSale117,59254.476.41M USD559,399Form 4

Common questions about Royalty Pharma's executives and insiders

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.